carmofur has been researched along with Cancer of Lung in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thus, this study was aimed to investigate the potential cytotoxic, antiproliferative and apoptosis-triggering effects of a newly developed SLN-Carmofur compound on human lung adenocarcinoma A549 cells." | 8.02 | Toward stimulating apoptosis in human lung adenocarcinoma cells by novel nano-carmofur compound treatment. ( Çömlekçi, E; Kutlu, HM; Vejselova Sezer, C, 2021) |
| "The antitumor activity of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in various schedules of long-term oral administration was examined in spontaneous mammary adenocarcinoma of SHN mice, an autochthonous tumor system." | 7.66 | Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma of mice. ( Hoshi, A; Iigo, M; Kuretani, K; Tokuzen, R, 1980) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) and its parent compound 5-fluorouracil (5-FU) were tested PO for antitumor activity against mouse colon adenocarcinoma 26 (colon 26), colon adenocarcinoma 38 (colon 38), and Lewis lung carcinoma." | 7.66 | Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil. ( Iida, H; Naganuma, K; Sakurai, Y; Tsukagoshi, S; Tsuruo, T, 1980) |
| " Thus, this study was aimed to investigate the potential cytotoxic, antiproliferative and apoptosis-triggering effects of a newly developed SLN-Carmofur compound on human lung adenocarcinoma A549 cells." | 4.02 | Toward stimulating apoptosis in human lung adenocarcinoma cells by novel nano-carmofur compound treatment. ( Çömlekçi, E; Kutlu, HM; Vejselova Sezer, C, 2021) |
| "We studied longitudinally inflammatory reactions and serum C-reactive protein (S-CRP) levels in 52 colorectal cancer patients treated with a median of six 3-weekly cycles of raltitrexed 1." | 3.71 | Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma. ( Elomaa, I; Joensuu, H; Orpana, A; Osterlund, P; Repo, H, 2002) |
| "The antitumor activity of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in various schedules of long-term oral administration was examined in spontaneous mammary adenocarcinoma of SHN mice, an autochthonous tumor system." | 3.66 | Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma of mice. ( Hoshi, A; Iigo, M; Kuretani, K; Tokuzen, R, 1980) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) and its parent compound 5-fluorouracil (5-FU) were tested PO for antitumor activity against mouse colon adenocarcinoma 26 (colon 26), colon adenocarcinoma 38 (colon 38), and Lewis lung carcinoma." | 3.66 | Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil. ( Iida, H; Naganuma, K; Sakurai, Y; Tsukagoshi, S; Tsuruo, T, 1980) |
| "S-1 could be a valuable agent for breast cancer treatments, since it showed clinical efficacy and mild toxicity, and can be given orally." | 1.33 | S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer. ( Aogi, K; Doihara, H; Nishimura, R; Ohsumi, S; Saeki, T; Taira, N; Takashima, S, 2006) |
| "Lung metastasis in mice bearing subcutaneous tumors was significantly inhibited by HCFU at doses of 100-150 mg kg(-1) day(-1) without severe toxic side-effects, when orally administered three times per week either from week 4 or week 6 to 9 weeks after implantation." | 1.30 | Induction of apoptosis in metastatic foci from human gastric cancer xenografts in nude mice and reduction of circulating tumor cells in blood by 5-FU and 1-hexylcarbamoyl-5-fluorouracil. ( Abe, A; Inada, K; Nakanishi, H; Tatematsu, M; Tsukamoto, T; Yasui, K, 1999) |
| "A case of renal cell carcinoma with multiple lung metastases successfully treated with interferon (IFN) following nephrectomy is reported." | 1.28 | [A case of renal cell carcinoma with lung metastases successfully treated by interferon-beta]. ( Horie, M; Kawada, Y; Kobayashi, S; Komeda, H; Kuriyama, M; Takahashi, Y; Yamada, S, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (61.54) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Çömlekçi, E | 1 |
| Kutlu, HM | 1 |
| Vejselova Sezer, C | 1 |
| Osterlund, P | 1 |
| Orpana, A | 1 |
| Elomaa, I | 1 |
| Repo, H | 1 |
| Joensuu, H | 1 |
| Taira, N | 1 |
| Aogi, K | 1 |
| Ohsumi, S | 1 |
| Takashima, S | 1 |
| Nishimura, R | 1 |
| Doihara, H | 1 |
| Saeki, T | 1 |
| Tokuzen, R | 1 |
| Iigo, M | 1 |
| Hoshi, A | 1 |
| Kuretani, K | 1 |
| Tsuruo, T | 1 |
| Iida, H | 1 |
| Naganuma, K | 1 |
| Tsukagoshi, S | 1 |
| Sakurai, Y | 1 |
| Nakanishi, H | 1 |
| Abe, A | 1 |
| Inada, K | 1 |
| Tsukamoto, T | 1 |
| Yasui, K | 1 |
| Tatematsu, M | 1 |
| Suzuki, T | 1 |
| Koizumi, J | 1 |
| Uchida, K | 1 |
| Shiraishi, H | 1 |
| Hori, M | 1 |
| Kanda, Y | 1 |
| Akazawa, S | 1 |
| Futatsugi, K | 1 |
| Fujiki, T | 1 |
| Saifuku, K | 1 |
| Yamamoto, K | 1 |
| Suzuki, F | 1 |
| Nakajima, T | 1 |
| Naoi, Y | 1 |
| Muraoka, M | 1 |
| Katsumi, T | 1 |
| Murayama, K | 1 |
| Komeda, H | 1 |
| Horie, M | 1 |
| Takahashi, Y | 1 |
| Kobayashi, S | 1 |
| Yamada, S | 1 |
| Kuriyama, M | 1 |
| Kawada, Y | 1 |
| Fukushima, K | 1 |
| Higashi, H | 1 |
| Takenaka, K | 1 |
| Kanematsu, T | 1 |
| Matsumata, T | 1 |
| Yoshida, Y | 1 |
| Sugimachi, K | 2 |
| Anai, H | 1 |
| Maehara, Y | 1 |
| Kusumoto, H | 1 |
| Masuda, H | 1 |
13 other studies available for carmofur and Cancer of Lung
| Article | Year |
|---|---|
Toward stimulating apoptosis in human lung adenocarcinoma cells by novel nano-carmofur compound treatment.
Topics: A549 Cells; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Fluorour | 2021 |
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2002 |
S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplas | 2006 |
Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma of mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Drug Administration Schedule; Female; Fluorouracil; | 1980 |
Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; In Vitro Techniques | 1980 |
Induction of apoptosis in metastatic foci from human gastric cancer xenografts in nude mice and reduction of circulating tumor cells in blood by 5-FU and 1-hexylcarbamoyl-5-fluorouracil.
Topics: Animals; Antigens, Nuclear; Antineoplastic Agents; Apoptosis; Cell Division; Dose-Response Relations | 1999 |
Carmofur-induced organic mental disorders.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Electroencephalography; Female; Fluorouracil; Follow-U | 1990 |
[A case of hepatocellular carcinoma (HCC) with lung metastasis which responded to chemotherapy with a single use of 1-hexylcarbamoyl-5-fluorouracil (HCFU)].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Lung Neopla | 1989 |
[A case of non-functioning adrenal cortical carcinoma with pulmonary and bony metastases].
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Antineoplastic Agents; Bone Neoplasms; Combined Modality Th | 1989 |
[A case of renal cell carcinoma with lung metastases successfully treated by interferon-beta].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Fluorouracil; Humans; Interferon Type I; Kidney Neopla | 1989 |
[Antitumor effects of 5-fluorouracil-bound organic silicon compound].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Ethyla | 1989 |
[1-Hexylcarbamoyl-5-fluorouracil (HCFU) effective in hepatocellular carcinoma metastatic to the lungs--a case report].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; | 1987 |
[Chemosensitivity testing for 5-FU and 5-FU derivatives using subrenal capsule assay].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colony-Forming Units Assay; Fluor | 1987 |